Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity

Journal of Cutaneous Pathology

Volumn 24, Issue 4, 1997, Pages 241-245

  McGinley, Kent M ^a   Bryant, Susan ^a   Kattine, Anthony A ^a   Fitzgibbon, James F ^a   Googe, Paul B ^a,b  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b Knoxville Dermatopathology Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEIOMYOMA; MALE; MUSCLE TUMOR; TUMOR GROWTH;

EID: 0030935717     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1997.tb01588.x     Document Type: Article

References (31)

1. Thompson JA Jr. Therapy for painful cutaneous leiomyomas. J Am Acad Dermatol 1985; 13: 865.
2. Cirkel U, Ochs H, Roehl A, Schneider HP. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone therapy. Analogue depot therapy. Acta Obstet Gynecol Scand 1994; 73: 328.
3. Hales HA, Peterson CM, Jones KP, Quinn JD. Leiomyomatosis peritonealis disseminata treated with a gonadotropin-releasing hormone agonist. A case report [published erratum appears in Am J Obstet Gynecol 1993; 169: 439] Am J Obstet Gynecol 1992; 167: 515.
4. Fernandez-Montoli ME, Diez-Gibert O, Samaniego JM, Balaguero L, Navarro MA. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment. Fertil Steril 1995; 63: 522.
5. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991; 96: 529.
6. Havel G, Dahlenfors R, Wedell B, Hogstrom L, Mark J. Cytogenetical observations and hormone receptor expression in five extra-uterine leiomyomas. Anticancer Res 1994; 14: 1935.
7. MarkJ, Havel G, Dahlenfors R, Wedell B. Cytogenetics of multiple uterine leiomyomas, parametrial leiomyoma and disseminated peritoneal leiomyomatosis. Anticancer Res 1991; 11: 33.
8. Kesari D, Gemer O, Segal S, Sibi J. Estrogen receptors in a urethral leiomyoma presenting in pregnancy [letter]. Int J Gynaecol Obstet 1994; 47: 59.
9. Battifora H. Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol 1991; 96: 669.
10. Battifora H, Mehta P, Ahn C. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. Applied Immunohistochemistry 1993; 1: 39.
11. Vollenhoven BJ, Pearce P, Herington AC, Healy DL. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women. Clin Endocrinol 1994; 40: 537.
12. Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 1995; 80: 1876.
13. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172: 14.
14. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992; 166: 746.
15. Stovall TG, Summit RL Jr, Washburn SA, Ling FW. Gonadotropin-releasing hormone agonist use before hysterectomy [see comments]. Am J Obstet Gynecol 1994; 170: 1748.
16. Uchida T, Tokumaru T, Kojima H, Nakagawaji K, Imaizumi M, Abe T. A case of multiple leiomyomatous lesions of the lung: an analysis of flow cytometry and hormone receptors. Surg Today 1992; 22: 265.
17. Lloveras B, Googe PB, Goldberg DE, Bhan AK. Estrogen receptors in skin appendage tumors and extramammary Paget's disease. Mod Pathol 1991; 4: 487.
18. Swanson PE, Mazoujian G, Mills SE, Campbell RJ, Wick MR. Immunoreactivity for estrogen receptor protein in sweat gland tumors. Am J Surg Pathol 1991; 15: 835.
19. Voytek TM, Ricci A Jr, Cartun RW. Estrogen and progesterone receptors in primary eccrine carcinoma. Mod Pathol 1991; 4: 582.
20. Esteban JM, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991; 4: 53.
21. Vollmer G, Gerdes J, Knuppen R. Quantification of estrogen and progesterone receptors from cryostat sectioned human tumor tissue: comparison of ligand binding and immunocytochemical assays. J Steroid Biochem 1989; 33: 41.
22. Shintaku P, Said JW. Detection of estrogen receptors with monoclonal antibodies in routinely processed formalinfixed paraffin sections of breast carcinoma. Use of DNase pretreatment to enhance sensitivity of the reaction. Am J Clin Pathol 1987; 87: 161.
23. Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinnsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 1992; 45: 125.
24. Saccanijotti G, Johnston SR, Salter J, Detre S, Dowsett M. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol 1994; 47: 900.
25. Kell DL, Kamel OW, Rouse RV. Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue. Appl Immunohistochem 1993; 4: 275.
26. Sahin AA, Ordonez NG. Quantitative estrogen receptor immunohistochemical analysis of breast cancer: Advantages and potential problems. Adv Anat Pathol 1996; 2: 97.
27. Battifora H. Immunocytochemistry of hormone receptors in routinely processed tissues. App Immunohisto 1994; 2: 143.
28. Esteban JM, Ahn C, Battifora H, Felder B. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer 1994; 102: S9.
29. Weedon D. Tumours of smooth and striated muscle. In: Systemic Pathology, 3rd edn. Vol. 9. The Skin. Edinburgh: Churchill Livingston, 1992: 915.
30. Piantelli M, Maggiano N, Ricci R, et al. Tamoxifen and Quercetin Interact with Type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 1995; 105: 248.
31. Lantta M, Karkkainen J, Wahlstrom T, Widholm O. Estradiol and progesterone receptors in gynecologic sarcomas. Acta Obstet Gynecol Scand 1984; 63: 505.